Biotechnology firm Pharming booked a lost of €15.1m in the first six months of this year, compared with €12.1m in the year earlier period.

The company’s operational costs rose over €2m, due to an increase in research costs connected to the registration of its drug Rhucin.
Pharming plans to submit a new registration request for the drug to the European Union in September. Rhucin is used to treat allergic swelling reactions known as angioedema.
The company said its finances would remain a top priority in the second half of the year and was in talks about raising more capital.